DeFi Daily News
Tuesday, November 17, 2026
Advertisement
  • Cryptocurrency
    • Bitcoin
    • Ethereum
    • Altcoins
    • DeFi-IRA
  • DeFi
    • NFT
    • Metaverse
    • Web 3
  • Finance
    • Business Finance
    • Personal Finance
  • Markets
    • Crypto Market
    • Stock Market
    • Analysis
  • Other News
    • World & US
    • Politics
    • Entertainment
    • Tech
    • Sports
    • Health
  • Videos
No Result
View All Result
DeFi Daily News
  • Cryptocurrency
    • Bitcoin
    • Ethereum
    • Altcoins
    • DeFi-IRA
  • DeFi
    • NFT
    • Metaverse
    • Web 3
  • Finance
    • Business Finance
    • Personal Finance
  • Markets
    • Crypto Market
    • Stock Market
    • Analysis
  • Other News
    • World & US
    • Politics
    • Entertainment
    • Tech
    • Sports
    • Health
  • Videos
No Result
View All Result
DeFi Daily News
No Result
View All Result
Home Markets Stock Market

A comprehensive guide to Zenas BioPharma’s IPO | AlphaStreet

Staff Correspondent by Staff Correspondent
August 27, 2024
in Stock Market
0 0
0
A comprehensive guide to Zenas BioPharma’s IPO | AlphaStreet
0
SHARES
0
VIEWS
Share on FacebookShare on TwitterShare on Telegram
Listen to this article

Zenas BioPharma, Inc. is among the latest healthcare companies to jump on the IPO bandwagon, filing its prospectus even as the market experiences significantly higher activity than in 2023. It is a clinical-stage global biopharmaceutical company engaged in developing and commercializing immunology-based therapies.

To List on Nasdaq

Zenas recently filed papers with the Securities and Exchange Commission, seeking to list on the Nasdaq Global Market under the symbol ZBIO. Meanwhile, the company is yet to reveal the number of shares being offered and the other terms of the offering. Morgan Stanley, Jefferies, ​Citigroup, and Guggenheim Securities are the bookrunners of the offering.

The management intends to use proceeds from the offering, together with existing cash, primarily to advance the clinical development of lead product candidate obexelimab, including the phase-3 trial for patients with IgG4-RD, phase-2 trial for patients with MS, phase-2 trial for patients with SLE, and the phase-2/3 trial for patients with wAIHA. The remainder of the fund will be used for working capital and other general corporate purposes.

Pipeline

Obexelimab is a bifunctional monoclonal antibody being developed to treat IgG4-related disease and lupus. IgG4-RD is a chronic fibro-inflammatory condition that can affect virtually all organ systems. The pipeline also includes clinical programs for the potential treatment of other immunology & inflammation indications which the company intends to develop and commercialize with partners. Zenas is led by its founder Leon O. Moulder, Jr., who also serves as the chief executive officer and chairman. Originally incorporated on November 12, 2019, the company’s principal executive offices are in Waltham, Massachusetts.

Zenas has raised $358.3 million from investors since its inception. It had $183.9 million in cash as of June 30, 2024. The company does not have any product candidates approved for commercial sale in any country and has not generated any revenue from product sales.

Important Numbers

In the six months ended June 30, 2024, Zenas incurred a loss of $65.78 million or $4.85 per share, compared to a loss of $48.14 million or $3.64 per share in the comparable period last year. Research and development expenses increased 87% year-over-year to $56.5 million during the period.

DeFi Daily News

Conclusion

As Zenas BioPharma prepares for its IPO and aims to list on the Nasdaq Global Market, the company’s focus on developing immunology-based therapies shows promise for the future. With the leadership of founder Leon O. Moulder, Jr., Zenas is targeting chronic conditions like IgG4-related disease and lupus with its lead product candidate obexelimab. The capital raised from the offering will further support the clinical trials and potential commercialization of these treatments.

Despite the challenges of not having any approved product candidates for sale or generating revenue, Zenas BioPharma’s pipeline and strategic partnerships indicate a strong commitment to driving innovation in the healthcare industry. Investors will be closely watching the company’s progress as it advances its clinical programs and works towards achieving its mission of improving patient outcomes.

Overall, Zenas BioPharma’s IPO presents an exciting opportunity for investors looking to support advancements in immunology-based therapies and contribute to the growth of a promising biopharmaceutical company.



Source link

Tags: AlphaStreetBioPharmasComprehensiveGuideIPOZenas
ShareTweetShare
Previous Post

Coupa Introduces a Variety of New Features on its Spend Management Platform

Next Post

Labor Day Sale at Wayfair: Get a Propane Patio Heater for Just $95.32 with Free Shipping and More Deals!

Next Post
Labor Day Sale at Wayfair: Get a Propane Patio Heater for Just $95.32 with Free Shipping and More Deals!

Labor Day Sale at Wayfair: Get a Propane Patio Heater for Just $95.32 with Free Shipping and More Deals!

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

No Result
View All Result
  • Trending
  • Comments
  • Latest
rewrite this title Coldcard Bitcoin Exploit Balloons to $88 Million as Attackers Keep Draining Wallets – Decrypt

rewrite this title Coldcard Bitcoin Exploit Balloons to $88 Million as Attackers Keep Draining Wallets – Decrypt

August 2, 2026

How to Claim ALL Your Amazon Prime Freebies

October 6, 2026
rewrite this title and make it good for SEO Aave Plans to Shut Down Six Blockchain Deployments in Strategic Network Cleanup – NFT Plazas

rewrite this title and make it good for SEO Aave Plans to Shut Down Six Blockchain Deployments in Strategic Network Cleanup – NFT Plazas

August 1, 2026
rewrite this title and make it good for SEOFigma is getting crushed in its post-IPO earnings debut; CEO Dylan Field is focused on AI’s long term power to ‘raise the ceiling’

rewrite this title and make it good for SEOFigma is getting crushed in its post-IPO earnings debut; CEO Dylan Field is focused on AI’s long term power to ‘raise the ceiling’

September 3, 2025

We Eat Out So Much So We Want To Open A Restaurant

October 17, 2026
rewrite this title Genius Sports Now Settles Contracts for Both Kalshi and Polymarket

rewrite this title Genius Sports Now Settles Contracts for Both Kalshi and Polymarket

August 8, 2026

The Dark Side of China’s Perfect Cars

November 17, 2026

“Bitcoin is Over…” Here’s What Comes Next

November 16, 2026

Bitcoin… This Is A Warning Sign. Stocks CRASHING Today

November 16, 2026

Zelle Partners With Solana🚀Biggest Crypto Adoption Catalyst EVER?

November 16, 2026

Regime Change Portfolio ⚠️ Darius Dale Warns of Exit Risk

November 16, 2026

Nvidia does not stop without Jensen Huang. | The 8:30

November 15, 2026
DeFi Daily

Stay updated with DeFi Daily, your trusted source for the latest news, insights, and analysis in finance and cryptocurrency. Explore breaking news, expert analysis, market data, and educational resources to navigate the world of decentralized finance.

  • About Us
  • Blogs
  • DeFi-IRA | Learn More.
  • Advertise with Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2024 Defi Daily.
Defi Daily is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Cryptocurrency
    • Bitcoin
    • Ethereum
    • Altcoins
    • DeFi-IRA
  • DeFi
    • NFT
    • Metaverse
    • Web 3
  • Finance
    • Business Finance
    • Personal Finance
  • Markets
    • Crypto Market
    • Stock Market
    • Analysis
  • Other News
    • World & US
    • Politics
    • Entertainment
    • Tech
    • Sports
    • Health
  • Videos

Copyright © 2024 Defi Daily.
Defi Daily is not responsible for the content of external sites.